The new facility will be in the Sorrento Valley and will house the company’s research, preclinical and clinical development, pharmaceutical sciences and administrative operations.
Barry Quart, president and CEO of Ardea, said: “Moving our two southern California facilities to San Diego’s biotechnology corridor is integral to our future growth and success, uniting the organization while providing access to a wealth of biotechnology and pharmaceutical industry expertise.”